(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene - 22024's Driving Clearing Robots: Master Suggestions and Surveys
- 3Vote in favor of your #1 Sort of Convenience for a Family
- 4NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 5Former 'Bachelorette' welcomes 1st baby via emergency c-section
- 21 Things You Ought to Never Tell Your Childless Companion
- Two more UN peacekeepers killed in southern Lebanon: UNIFIL
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
- Astronomers spot white dwarf star creating a colorful shockwave
- Allow Innovative Progressions To have a Tremendous Effect
- 'Fertiliser costs mean I'm better off not planting'
- Brazil expands pesticide packaging reverse logistics
- Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
